Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Gilteritinib prolongs OS in FLT3+ R/R AML: Phase 3 ADMIRAL results

Alexander Perl • 15 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia Gilteritinib
ADMIRAL

Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the results of the Phase III ADMIRAL trial (NCT02421939) of gilteritinib in FLT3+ relapsed/refractory acute myeloid leukemia (AML) at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Alexander Perl

3:03
QuANTUM-First: FLT3-ITD-specific MRD to assess benefits of quizartinib in FLT3-ITD+ AML
Alexander Perl • 9 Dec 2023
2:46
Update of the ADMIRAL trial: gilteritinib vs salvage chemotherapy prior to HSCT in FLT-3 mutated AML
Alexander Perl • 9 Dec 2023
2:07
Comparing midostaurin to next-generation FLT3 inhibitors in the frontline treatment of FLT3-ITD AML
Alexander Perl • 9 Jun 2023
0:44
The clinical meaning of MRD below the threshold of mCR in AML
Alexander Perl • 9 Jun 2023

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals